{"id":1349,"date":"2016-02-01T12:01:00","date_gmt":"2016-02-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/antidote-gegen-die-neuen-oralen-antikoagulanzien-noak"},"modified":"2016-02-01T12:01:00","modified_gmt":"2016-02-01T11:01:00","slug":"antidote-gegen-die-neuen-oralen-antikoagulanzien-noak","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/antidote-gegen-die-neuen-oralen-antikoagulanzien-noak","title":{"rendered":"Antidote gegen die neuen oralen Antikoagulanzien (NOAK)"},"content":{"rendered":"<p>Kein Antidot verf\u00fcgbar \u2013 dieser Mangel wird in der Diskussion um die nicht-Vitamin-K abh\u00e4ngigen neuen oralen Antikoagulanzien (NOAK) als wichtiger Nachteil angef\u00fchrt (vgl. 1). Mit bedeutsamen Blutungen unter NOAK-Therapie ist immerhin bei 1,6-3,6% der Patienten pro Jahr zu rechnen, je nach verabreichter Dosis und zu Grunde liegender Nierenfunktion (2). Derzeit m\u00fcssen je nach verwendetem NOAK [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kein Antidot verf\u00fcgbar \u2013 dieser Mangel wird in der Diskussion um die nicht-Vitamin-K abh\u00e4ngigen neuen oralen Antikoagulanzien (NOAK) als wichtiger Nachteil angef\u00fchrt (vgl. 1). Mit bedeutsamen Blutungen unter NOAK-Therapie ist immerhin bei 1,6-3,6% der Patienten pro Jahr zu rechnen, je nach verabreichter Dosis und zu Grunde liegender Nierenfunktion (2). Derzeit m\u00fcssen je nach verwendetem NOAK [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3249,3252,3250,3251,137,1322,3248,2305,1314,1312,2068,3253,1328,1327,3247,2304],"class_list":["post-1349","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-andexanet","tag-annexa-a-studie","tag-annexa-r-studie","tag-antidote","tag-antikoagulanzien","tag-apixaban","tag-ciraparantag","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-idarucizumab","tag-neue-orale-antikoagulanzien","tag-noak","tag-re-verse-ad-studie","tag-rivaroxaban"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1349"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1349\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}